Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes

Expert Opinion on Biological Therapy

Volumn 10, Issue 8, 2010, Pages 1181-1195

  Yu, Mingke ^a   Vajdy, Michael ^a  

^a EpitoGenesis Inc   (United States)

Author keywords

HIV; Mucosa; Oral; Rectal; Vaccine; Vagina

Indexed keywords

ADJUVANT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B LYMPHOCYTE; CELL STRUCTURE; DISEASE TRANSMISSION; DRUG DELIVERY SYSTEM; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MOUTH MUCOSA; MUCOSAL IMMUNITY; NONHUMAN; ORAL SEXUAL CONTACT; RECTUM MUCOSA; REVIEW; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VAGINA MUCOSA; ANIMAL; FEMALE; HIV INFECTIONS; IMMUNOLOGY; INTESTINE MUCOSA; INTRAVAGINAL DRUG ADMINISTRATION; MALE; MUCOSA; ORAL DRUG ADMINISTRATION; PATHOLOGY; RECTAL DRUG ADMINISTRATION; TRANSMISSION; VIROLOGY;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; AIDS VACCINES; ANIMALS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; MALE; MOUTH MUCOSA; MUCOUS MEMBRANE;

EID: 77954672442     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.496776     Document Type: Review

References (150)

1. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009;6:20-28
2. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005;5:783-792
3. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 2009;183:6883-6892
4. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6:148-158
5. Vajdy M. Current efforts on generation of optimal immune responses against HIV through mucosal immunisations. Drugs R D 2006;7:267-288
6. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:S45-53
7. Cafaro A, Macchia I, Maggiorella MT, et al. Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. Adv Exp Med Biol 2009;655:189-242
8. Vajdy M, Singh M. Intranasal delivery of vaccines against HIV. Expert Opin Drug Deliv 2006;3:247-259
9. Belyakov IM, Wyatt LS, Ahlers JD, et al. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol 1998;72:8264-8272
10. Stevceva L, Alvarez X, Lackner AA, et al. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8+ T-cell responses in mucosal tissues of macaques. J Virol 2002;76:11659-11676
11. Di Fabio S, Medaglini D, Rush CM, et al. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine 1998;16:485-492
12. Zhou Q, Hidajat R, Peng B, et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV (mac251). Vaccine 2007;25:8021-8035
13. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002;41:661-680
14. Song JH, Nguyen HH, Cuburu N, et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008;105:1644-1649
15. Malik B, Goyal AK, Mangal S, et al. Implication of gut immunology in the design of oral vaccines. Curr Mol Med 2010;10:47-70
16. Kelly PJ. Clinically oriented anatomy. Lippincott Williams &Wilkins, Philadelphia; 1999
17. Fujimura Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch 2000;436:560-566
18. Pope M. Mucosal dendritic cells and immunodeficiency viruses. J Infect Dis 1999;179:S427-30
19. Challacombe SJ, Naglik JR. The effects of HIV infection on oral mucosal immunity. Adv Dent Res 2006;19:29-35
20. Kuper CF, Koornstra PJ, Hameleers DM, et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992;13:219-224
21. Tschernig T, Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 2000;68:1-8
22. Lewis DJ, Huo Z, Barnett S, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009;4:e6999
23. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998;1:15-30
24. Hao J, Heng PW. Buccal delivery systems. Drug Dev Ind Pharm 2003;29:821-832
25. Wu AM, Csako G, Herp A. Structure, biosynthesis, and function of salivary mucins. Mol Cell Biochem 1994;137:39-55
26. Desvignes C, Esteves F, Etchart N, et al. The murine buccal mucosa is an inductive site for priming class I-restricted CD8+ effector T cells in vivo. Clin Exp Immunol 1998;113:386-393
27. Etchart N, Desmoulins PO, Chemin K, et al. Dendritic cells recruitment and in vivo priming of CD8+ CTL induced by a single topical or transepithelial immunization via the buccal mucosa with measles virus nucleoprotein. J Immunol 2001;167:384-391
28. O'Hehir RE, Sandrini A, Anderson GP, Rolland JM. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr Med Chem 2007;14:2235-2244
29. Brandtzaeg P. Humoral immune response patterns of human mucosae: induction and relation to bacterial respiratory tract infections. J Infect Dis 1992;165:S167-76
30. Boyaka PN, Wright PF, Marinaro M, et al. Human nasopharyngeal-associated lymphoreticular tissues: functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils. Am J Pathol 2000;157:2023-2035
31. Wu X, Jackson S. Plasma and salivary IgA subclasses and IgM in HIV-1-infected individuals. J Clin Immunol 2002;22:106-115
32. Graeme-Cook F, Bhan AK, Harris NL. Immunohistochemical characterization of intraepithelial and subepithelial mononuclear cells of the upper airways. Am J Pathol 1993;143:1416-1422
33. Liuzzi G, Chirianni A, Clementi M, et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996;10:F51-6
34. Sullivan PS, Salazar L, Buchbinder S, Sanchez TH. Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. AIDS 2009;23:1153-1162
35. Edwards S, Carne C. Oral sex and the transmission of viral STIs. Sex Transm Infect 1998;74:6-10 (Pubitemid 28201974)
36. Rozenbaum W, Gharakhanian S, Cardon B, et al. HIV transmission by oral sex. Lancet 1988;1:1395
37. Joag SV, Adany I, Li Z, et al. Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS. J Virol 1997;71:4016-4023
38. European Collaborative Study. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991;337:253-260
39. Van de Perre P. Transmission of human immunodeficiency virus type 1 through breast-feeding: how can it be prevented? 4 J Infect Dis 1999;179(Suppl 3):S405-7
40. Han Y, Ventura CL, Black KP, et al. Productive human immunodeficiency virus-1 infection of epithelial cell lines of salivary gland origin. Oral Microbiol Immunol 2000;15:82-88
41. Fox PC. Salivary gland involvement in HIV-1 infection. Oral Surg Oral Med Oral Pathol 1992;73:168-70
42. McNeely TB, Dealy M, Dripps DJ, et al. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995;96:456-464
43. Kumar RB, Maher DM, Herzberg MC, Southern PJ. Expression of HIV receptors, alternate receptors and co-receptors on tonsillar epithelium: implications for HIV binding and primary oral infection. Virol J 2006;3:25
44. Magerus-Chatinet A, Yu H, Garcia S, et al. Galactosyl ceramide expressed on dendritic cells can mediate HIV-1 transfer from monocyte derived dendritic cells to autologous T cells. Virology 2007;362:67-74
45. Quinones-Mateu ME, Lederman MM, Feng Z, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003;17:F39-48
46. Habte HH, Mall AS, de Beer C, et al. The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of human immunodeficiency virus type 1 in an inhibition assay. Virol J 2006;3:99
47. Milush JM, Kosub D, Marthas M, et al. Rapid dissemination of SIV following oral inoculation. AIDS 2004;18:2371-2380
48. Milush JM, Stefano-Cole K, Schmidt K, et al. Mucosal innate immune response associated with a timely humoral immune response and slower disease progression after oral transmission of simian immunodeficiency virus to rhesus macaques. J Virol 2007;81:6175-6186
49. Challacombe SJ, Sweet SP. Oral mucosal immunity and HIV infection: current status. Oral Dis 2002;8(Suppl 2):55-62
50. Coutsoudis A, Coovadia HM, Wilfert CM. HIV, infant feeding and more perils for poor people: new WHO guidelines encourage review of formula milk policies. Bull World Health Organ 2008;86:210-214
51. Ait-Khaled M, Lyall EG, Stainsby C, et al. Intrapartum mucosal exposure to human immunodeficiency virus type 1 [HIV-1] of infants born to HIV-1-infected mothers correlates with maternal plasma virus burden. J Infect Dis 1998;177:1097-1100
52. Greenier JL, Van Rompay KK, Montefiori D, et al. Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. Virol J 2005;2:11
53. Hone DM, Wu S, Powell RJ, et al. Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. J Biotechnol 1996;44:203-207
54. Chin'ombe N, Bourn WR, Williamson AL, Shephard EG. Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. Virol J 2009;6:87
55. Stevens R, Howard KE, Nordone S, et al. Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus. J Virol 2004;78:8210-8218
56. Jiang S, Rasmussen RA, Nolan KM, et al. Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine 2007;25:7470-7479
57. Kawahara M, Hashimoto A, Toida I, Honda M. Oral recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin Immunol 2002;105:326-331
58. Mercier GT, Nehete PN, Passeri MF, et al. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 2007;25:8687-8701
59. Zhou Q, Hidajat R, Peng B, et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV (mac251). Vaccine 2007;25:8021-8035
60. Demberg T, Florese RH, Heath MJ, et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007;81:3414-3427
61. Kaneko H, Bednarek I, Wierzbicki A, et al. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 2000;267:8-11
62. Jirathitikal V, Bourinbaiar AS. Effect of an oral therapeutic HIV-1 vaccine on AIDS patients with CD4 count above 250 cells/mm3. Acta Virol 2004;48:73-78
63. Takamura S, Niikura M, Li TC, et al. DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther 2004;11:628-635
64. Guetard D, Greco R, Cervantes Gonzalez M, et al. Immunogenicity and tolerance following HIV-1/HBV plant-based oral vaccine administration. Vaccine 2008;26:4477-4485
65. Ramirez YJ, Tasciotti E, Gutierrez-Ortega A, et al. Fruit-specific expression of the human immunodeficiency virus type 1 tat gene in tomato plants and its immunogenic potential in mice. Clin Vaccine Immunol 2007;14:685-692
66. Karasev AV, Foulke S, Wellens C, et al. Plant based HIV-1 vaccine candidate: tat protein produced in spinach. Vaccine 2005;23:1875-1880
67. Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J Immunol 2007;179:5633-5638
68. Wu HY. Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus? Clin Immunol 2009;130:111-122
69. Shacklett BL. Cell-mediated immunity t HIV in the female reproductive tract. J Reprod Immunol 2009;83:190-195
70. Bergmeier LA, Lehner T. Innate and adaptive mucosal immunity in protection against HIV infection. Adv Dent Res 2006;19:21-28
71. Barnett SW, Srivastava IK, Kan E, et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008;22:339-348
72. Yeaman GR, White HD, Howell A, et al. The mucosal immune system in th human female reproductive tract: potential insights into the heterosexual transmission of HIV. AIDS Res Hum Retroviruses 1998;14(Suppl 1):S57-62
73. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa afte intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000;74:6087-6095
74. Shacklett BL. Cell mediated immunity HIV in the female reproductive tract. J Reprod Immunol 2009;83:190-5
75. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. 1996;183:215-225
76. Miller CJ, McChesney M, Moore PF. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab Invest 1992;67:628-634
77. Bjercke S, Scott H, Braathen LR, Thorsby E. HLA-DR-expressing Langerhans'-like cells in vaginal and cervical epithelium. 1983;62:585-589
78. Edwards JN, Morris HB. Langerhans' cells and lymphocyte subsets in the female genital tract. 1985;92:974-982
79. Hocini H, Bomsel M. Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. J Infect Dis 1999;179(Suppl 3):S448-53
80. Miller CJ, Lu FX. Anti-HIV and -SIV immunity in the vagina. Int Rev Immunol 2003;22:65-76
81. Padian NS, Shiboski SC, Jewell NP. Female-to-male transmission of human immunodeficiency virus. JAMA 1991;266:1664-1667
82. Le Tortorec A, Le Grand R, Denis H, et al. Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. PLoS One 2008;3:e1792
83. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007;21:1723-1730
84. Moldoveanu Z, Huang WQ, Kulhavy R, et al. Human male genital tract secretions: both mucosal and systemic immune compartments contribute to the humoral immunity. J Immunol 2005;175:4127-4136
85. Matoba N, Geyer BC, Kilbourne J, et al. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR (649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006;24:5047-5055
86. Esquivel-Perez R, Moreno-Fierros L. Mucosal and systemic adjuvant effects of cholera toxin and Cry1Ac protoxin on the specific antibody response to HIV-1 C4/V3 peptides are different and depend on the antigen co-administered. Viral Immunol 2005;18:695-708
87. Buonaguro L, Visciano ML, Tornesello ML, et al. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005;79:7059-7067
88. Hinkula J, Devito C, Zuber B, et al. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine 2006;24:4494-4497
89. Kent SJ, Dale CJ, Ranasinghe C, et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 2005;23:5009-5021
90. Devito C, Zuber B, Schroder U, et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 2004;173:7078-7089
91. Locher CP, Witt SA, Ashlock BM, et al. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine 2004;22:2261-2272
92. Staats HF, Nichols WG, Palker TJ. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol 1996;157:462-472
93. Bielinska AU, Janczak KW, Landers JJ, et al. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008;24:271-281
94. Parr MB, Parr EL. Immunohistochemical localization of immunoglobulins A, G and M in the mouse female genital tract. J Reprod Fertil 1985;74:361-370
95. Johansson EL, Rask C, Fredriksson M, et al. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 1998;66:514-520
96. Thapar MA, Parr EL, Bozzola JJ, et al. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine 1991;9:129-133
97. Vajdy M, Gardner J, Neidleman J, et al. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J Infect Dis 2001;184:1613-1616
98. Gupta S, Janani R, Bin Q, et al. Characterization of HIV-gag-specific IFNgamma-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol 2005;79:7135-7145
99. Wira CR, Richardson J, Prabhala R. Endocrine regulation of mucosal immunity: effect of sex hormones and cytokines on the afferent and efferent arms of the immune system in the female reproductive tract. In: Ogra PL, Mestecky J, Lamm ME, et al.; editors, Handbook of mucosal immunology. Academic Press, New York; 1994. p. 705-718
100. Di Tommaso A, Saletti G, Pizza M, et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 1996;64:974-979
101. Bergquist C, Johansson EL, Lagergard T, et al. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997;65:2676-2684
102. Gherardi MM, Najera JL, Perez-Jimenez E, et al. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol 2003;77:7048-7057
103. Gherardi MM, Perez-Jimenez E, Najera JL, Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 2004;172:6209-6220
104. Huang X, Liu L, Ren L, et al. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. Vaccine 2007;25:8874-8884 (Pubitemid 350192050)
105. Huang X, Xu J, Qiu C, et al. Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses. Vaccine 2007;25:2620-2629 (Pubitemid 46400929)
106. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-549
107. Egan MA, Chong SY, Rose NF, et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 2004;20:989-1004
108. Ferko B, Stasakova J, Sereinig S, et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J Virol 2001;75:8899-8908
109. Ferko B, Katinger D, Grassauer A, et al. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis 1998;178:1359-1368
110. Kang SM, Guo L, Yao Q, et al. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol 2004;78:9624-9632
111. Koopman G, Bogers WM, van Gils M, et al. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J Med Virol 2007;79:474-482
112. Miyake A, Akagi T, Enose Y, et al. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J Med Virol 2004;73:368-377
113. Jiang JQ, Patrick A, Moss RB, Rosenthal KL. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J Virol 2005;79:393-400
114. Kawahara M, Matsuo K, Nakasone T, et al. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. Vaccine 21:158-166
115. Golding B, Eller N, Levy L, et al. Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus. Vaccine 2002;20:1445-1450
116. Li Z, Zhang M, Zhou C, et al. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J Immunol 2008;180:2504-2513
117. Pialoux G, Hocini H, Perusat S, et al. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: The ANRS VAC14 study. Vaccine 2008;26:2657-2666
118. Mestecky J, Fultz PN. Mucosal immune system of the human genital tract. J Infect Dis 1999;179:S470-4
119. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95-102
120. Pereira LH, Embil JA, Haase DA, Manley KM. Prevalence of human immunodeficiency virus in the patient population of a sexually transmitted disease clinic. Association with syphilis and gonorrhea. Sex Transm Dis 1992;19:115-120
121. Vajdy M, Veazey RS, Knight HK, et al. Differential effects of simian immunodeficiency virus infection on immune inductive and effector sites in the rectal mucosa of rhesus macaques. Am J Pathol 2000;157:485-495
122. Belyakov IM, Wyatt LS, Ahlers JD, et al. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol 1998;72:8264-8272
123. Karpenko LI, Nekrasova NA, Ignat'ev GM, et al. Immune response in oral and rectal immunization by the attenuated strain of salmonella carrying the HIV DNA-vaccine. Vopr Virusol 2003;48:16-20
124. Wang SW, Bertley FM, Kozlowski PA, et al. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 2004;20:846-859
125. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74
126. Stevceva L, Alvarez X, Lackner AA, et al. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIVgpe recombinant vaccine result in gag-specific CD8+ T-cell responses in mucosal tissues of macaques. J Virol 2002;76:11659-11676
127. Vagenas P, Williams VG, Piatak M Jr, et al. Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr 2009;52:433-442
128. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Mucosal vaccination strategies for women. J Infect Dis 1999;179(Suppl 3):S493-8
129. Lehner T, Tao L, Panagiotidi C, et al. Mucosal model of genital immunization in male rhesus macaques with a recombinant simian immunodeficiency virus p27 antigen. J Virol 1994;68:1624-1632
130. Vajdy M. Current efforts on generation of optimal immune responses against HIV through mucosal immunisations. Drugs R D 2006;7:267-288
131. Trujillo-Vargas CM, Mayer KD, Bickert T, et al. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses. Clin Exp Allergy 2005;35:1003-1013
132. Bansal GP, Malaspina A, Flores J. Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances. Curr Opin Mol Ther 2010;12:39-46 rotavirus infection. J Virol 1998;72:726-730
133. Parr EL, Parr MB. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J Virol 1998;72:5137-5145
134. D'Ambrosio D, Panina-Bordignon P, Sinigaglia F. Chemokine receptors in inflammation: an overview. J Immunol Methods 2003;273:3-13
135. Heeney JL, Teeuwsen VJ, van Gils M, et al. beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci USA 1998;95:10803-8 145.
136. Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009;106:19940-19945
137. Csencsits KL, Walters N, Pascual DW. Cutting edge: dichotomy of homing receptor dependence by mucosal effector B cells: alphaE versus L-selectin. J Immunol 2001;167:2441-2445
138. Butcher EC, Williams M, Youngman K, et al. Lymphocyte trafficking and regional immunity. Adv Immunol 1999;72:209-253
139. Kuklin NA, Rott L, Feng N, et al. Protective intestinal anti-rotavirus B cell immunity is dependent on alpha4beta7 integrin expression but does not require IgA antibody production. J Immunol 2001;166:1894-1902
140. Quiding-Jarbrink M, Nordstrom I, Granstrom G, et al. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J Clin Invest 1997;99:1281-1286
141. Csencsits KL, Jutila MA, Pascual DW. Mucosal addressin expression and binding interactions with naive lymphocytes vary among the cranial, oral, and nasal-associated lymphoid tissues. Eur J Immunol 2002;32:3029-3039
142. Ghaleb M, Hamad M, Abu-Elteen KH. Vaginal T. lymphocyte population kinetics during experimental vaginal candidosis: evidence for a possible role of CD8+ T cells in protection against vaginal candidosis. Clin Exp Immunol 2003;131:26-33
143. Hawkins RA, Rank RG, Kelly KA. Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo. Infect Immun 2000;68:5587-5594
144. Perry LL, Feilzer K, Portis JL, Caldwell HD. Distinct homing pathways direct T lymphocytes to the genital and intestinal mucosae in Chlamydia-infected mice. J Immunol 1998;160:2905-2914
145. Rose JR, Williams MB, Rott LS, et al. Expression of the mucosal homing receptor alpha4beta7 correlates with the ability of CD8+ memory T cells to clear rotavirus infection. J Virol 1998;72:726-730
146. Parr EL, Parr MB. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J Virol 1998;72:5137-5145
147. D'Ambrosio D, Panina-Bordignon P, Sinigaglia F. Chemokine receptors in inflammation: an overview. J Immunol Methods 2003;273:3-13
148. Heeney JL, Teeuwsen VJ, van Gils M, et al. beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci USA 1998;95:10803-8 145.
149. Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009;106:19940-19945
150. Poles MA, Barsoum S, Yu W, et al. Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gamma delta T cells despite suppressive therapy. J Virol 2003;77:10456-10467